Alexza's Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care ...(as completed Phase 2 testing. AZ-104 (St...),Health
Navigation Links
Alexza's Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
Date:3/7/2008
as completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
'/>"/>
| SOURCE Alexza Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. New! Pull Back the Corporate Curtain at www.LazardUnveiled.org
2. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
3. New WBL Foundation Survey Shows Robust Pool of Women Available for Corporate Board Service
4. Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008
5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
6. Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference
7. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
8. Leventhal Weight Loss Incorporated President Mark Leventhal to Address Frederick County Bar
9. PreMD Initiates FDA Review Process and Provides Corporate Update
10. Michael Beland Named as OrthoSynetics(TM) Corporate Controller
11. Arizona-Based Healthy Lifestyle Corporate Events Helps Football Fans Commit to Good Health
Post Your Comments:
(Date:12/15/2009)... -- Connectyx Technologies Holding Group Inc. (Pink Sheets: ... a higher listing level on the Pink Sheets ... positions Connectyx as a Transparent Company with Adequate ... President Ronn Schuman stated, "We are excited to ... to become a fully reporting company. This ...
(Date:12/15/2009)... clean transition to new coding system. , ... ... -- The American Academy of Professional Coders ( AAPC ) ... for health plans across the country beginning January. Developed specifically ... and reimbursement experts, the on-site trainings are designed to enable ...
(Date:12/15/2009)... your trust as the most caring, conscientious practice you have ever ... the Dermatology Center of Dallas, we can help to achieve this ... ... (PRWEB) December 15, 2009 -- The Dermatology Center of Dallas, a ... arrival of Jeri Beth “J.B.” Foshee, MD in their practice. ...
(Date:12/15/2009)... Marketstrat is pleased to announce the release of a new ... addresses world markets for clinical devices used to treat and ... ... CA (PRWEB) December 15, 2009 -- Marketstrat is pleased to ... Markets Worldwide.” The report specifically addresses world markets for ...
(Date:12/14/2009)... Young Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, and ... -- Nearly all unmarried young adults ages 18-29 believe ... men and 86% of women) and say that it ... now (86% of men and 88% of women), according ... Prevent Teen and Unplanned Pregnancy. Even so: ,, ...
Breaking Medicine News(10 mins):Health News:Connectyx Attains 'Current Listing' Status on Pink Sheets Exchange 2Health News:Connectyx Attains 'Current Listing' Status on Pink Sheets Exchange 3Health News:AAPC Now Offers On-site ICD-10 Training for Health Plans Nationwide 2Health News:AAPC Now Offers On-site ICD-10 Training for Health Plans Nationwide 3Health News:Jeri Beth “J.B.” Foshee, MD Joins Dermatology Center of Dallas 2Health News:Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail 2Health News:Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail 3Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3[0] Connectyx Attains 'Current Listing' Status on Pink Sheets Exchange[0] AAPC Now Offers On-site ICD-10 Training for Health Plans Nationwide[0] Jeri Beth “J.B.” Foshee, MD Joins Dermatology Center of Dallas [0] Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail [1] Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference
... mumps beginning in Nova Scotia and now spreading in Ontario. ... affected. ,The latest outbreak of five people in ... has put health officials in top alert. ,Public-health ... booster shot, as the latest attacks prove that those vaccinated ...
... own wife or sons keep surfacing with monotonous regularity, especially from ... a South Carolina man held his wife and two sons captive ... since been sent to jail. ,The man identified as ... only that room was found tidy when the police raided ...
... more likely than men to develop osteoporosis, or porous bone, ... which can lead to debilitating - or even life-threatening - ... causes of osteoporosis are numerous, but in women, low estrogen ... ,As for men - new research at Washington University ...
... and the consequent quarantine of a woman has cost the ... cough up $75,000 dollars now. ,Based on ... case manager who had worked with high-risk obstetrics patients, isolated ... of February, said Deputy County Attorney Lori Alesio and Ryan's ...
... been unaffected by the rapidly increasing price of gas, which ... some parts of the United States . And consumers arent ... University professor has found. ,Research conducted by Wayne ... documents that Americans work attitudes have been affected as the ...
... ,"We call them dates," she said of the men with whom she ... dark hair off her slight shoulders and out of her smoky eyes. ... her large hands and Adam's apple seem obvious. But at first -- ... wasn't a girl her entire life. ,She prostitutes herself "about ...
Other Medicine News:Health News:Mumps Breaks Out In Canada 2Health News:Man Keeps Wife and Sons in Maggot-infested House 2Health News:Estrogen is Important for Bone Health in Men as Well as Women 2Health News:US County to Compensate Woman Wrongly Quarantined for TB 2Health News:Higher Gas Prices Leave Many Workers Running on Empty 2Health News:Making Change: The Cost of Being Transgender 2Health News:Making Change: The Cost of Being Transgender 3Health News:Making Change: The Cost of Being Transgender 4Health News:Making Change: The Cost of Being Transgender 5(Date:12/14/2009)... Seven leading cancer physicians ... Oncology Research participated in studies ... 2009 San Antonio Breast Cancer ... the Henry B. Gonzalez Convention ... . Fifteen others presented their ...
(Date:12/14/2009)... BEACH, Fla., Dec. 14 Perry Baromedical, ... years, announces the launch of the Sigma Elite, ... technology of the Sigma Elite is available on ... ) and has a Patent Pending. ,, The ... Data Capture Via Computerized System for Each ...
(Date:12/14/2009)... Diagnostics, Inc. is pleased to announce that the ... patent number 7,599,057 titled "Method and Apparatus for ... the company. The patent covers the core technology ... issuance of this patent supports the underlying strategy ... and commercialization," said Dave Dingott, CEO and President ...
Breaking Medicine Technology:US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2Chinese Devil Dung Plant Could Be a Swine Flu Fighter 56608 1Some Parents Arent Giving Kids Pain Meds Post Surgery 56606 1Some Parents Arent Giving Kids Pain Meds Post Surgery 56606 2Some Parents Arent Giving Kids Pain Meds Post Surgery 56606 3Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 1Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 2Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 3Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 4Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 5[0] US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium[0] Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability[0] U.S. Patent Office Issues Sword Diagnostics Patent for Highly Sensitive Immunodetection Technology
... and favorable safety ... ... IDIX ), a biopharmaceutical company engaged,in the discovery and development ... today announced that it has completed the,proof-of-concept study evaluating IDX899, a ...
... on Schedule with Two Abstracts Accepted for ... Release in November 2008, BRIDGEWATER, N.J., Sept. ... focused on the treatment of,cardiovascular and metabolic disease, ... to the Company,s board of directors., Peter ...
Other Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein G - .25 OD per sq. cm....
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Onyx Liquid Embolic System is a device utilized for the pre-surgical embolization of arteriovenous malformations (AVMs)....
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |